

Guidance on the preparation of an Annex XV dossier for the identification of substances of very high concern

Version 2.1
October 2018



Legal Notice

This document aims to assist users in complying with their obligations under the REACH Regulation. However, users are reminded that the text of the REACH Regulation is the only authentic legal reference and that the information in this document does not constitute legal advice. Usage of the information remains under the sole responsibility of the user. The European Chemicals Agency does not accept any liability with regard to the use that may be made of the information contained in this document.

Guidance on the preparation of an Annex XV dossier for the identification of substances of very high concern

Reference: ECHA-18-G-09-EN

Catalogue Number: ED-03-18-290-EN-N

ISBN: 978-92-9020-840-2

DOI: 10.2823/063112

Publication date: October 2018

Language: EN

© European Chemicals Agency, 2018

If you have questions or comments in relation to this document, please send them (quote the reference and issue date) using the information request form. The information request form can be accessed *via* the Contact page at:

<https://echa.europa.eu/contact>

European Chemicals Agency

Mailing address: P.O. Box 400, FI-00121 Helsinki, Finland

Visiting address: Annankatu 18, Helsinki, Finland

Document History

Version	Changes	Date
Version 1.0	First edition (original unnumbered version).	June 2007
Version 2.0	<p>Second edition. The second edition of this document involved a complete overhaul of the text resulting in a reduction in the amount of detailed guidance given within this document itself. Instead, references are now given within the document to where specific instructions on how to prepare an Annex XV SVHC dossier can be found, including where to access the template for use in generating the Annex XV SVHC report.</p> <p>The revision was necessary in order to take into account actual experience gained by the Member State Competent Authorities and ECHA in the preparation of dossiers and real working practices and to take account of the amendment of Annex XIII of REACH (according to Commission Regulation (EU) No 253/2011 of 15 March 2011, OJ L 69 7 16.3.2011). Most of the content of the previous version of the guidance had been written before REACH came into force and therefore before real experience was available on implementing the processes it described.</p> <p>In addition, the title of the document has been amended slightly to "Guidance on the preparation of an Annex XV <i>dossier for the identification of substances of very high concern</i>" to better align it with the text of Annex XV itself.</p>	February 2014
Version 2.1	<p>Corrigendum:</p> <ul style="list-style-type: none"> - removal of the references to IUCLID/technical dossier; - editorial improvements. 	October 2018

Preface

This document describes how the authorities (Member States Competent Authorities or the European Chemicals Agency) can prepare a dossier in accordance with Annex XV to identify a substance of very high concern under REACH. It is part of a series of guidance documents that aim to help all stakeholders with their preparation for fulfilling their obligations under the REACH Regulation. These documents cover detailed guidance for a range of essential REACH processes as well as for some specific scientific and/or technical methods that industry or authorities need to make use of under REACH.

These guidance documents can be obtained *via* the website of the European Chemicals Agency (<https://echa.europa.eu/guidance-documents/guidance-on-reach>).

The legal references for the document are Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006, concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (the REACH Regulation)¹ and Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008, on classification, labelling and packaging of substances and mixtures².

¹ Corrigendum to Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006) as amended.

² Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (OJ L 353, 31.12.2008, p.1) as amended.

Table of Contents

1. INTRODUCTION	6
2. LEGAL FRAMEWORK.....	6
3. PREPARATION OF AN ANNEX XV DOSSIER FOR THE IDENTIFICATION OF SUBSTANCES OF VERY HIGH CONCERN (ARTICLE 57 OF REACH).....	7
3.1 Before starting to prepare a dossier	7
3.2 Preparing a dossier	8
3.3 Further guidance and support	8
3.4 What to do when an Annex XV dossier is not appropriate	9

1. Introduction

This document provides technical guidance to the Member States and the European Chemicals Agency on the preparation of a dossier in accordance with Annex XV to the REACH Regulation. It gives guidance on how to propose and justify the identification of substances of very high concern ('SVHCs') in accordance with the procedure set out in Article 59 of REACH (hereinafter referred to as an 'Annex XV SVHC dossier'). In this document, the term 'Authority' is used to refer to the Agency (i.e. ECHA) or any Member State competent authority developing an Annex XV SVHC dossier. Where the term SVHC is used in this guidance, it refers to all substances covered by Article 57 of REACH. In this document, Regulation 1907/2006 is referred to as the REACH Regulation or REACH. Regulation 1272/2008 is referred to as the CLP Regulation or CLP.

2. Legal framework

The authorisation procedure aims to ensure that the risks from SVHCs are properly controlled and that these substances are progressively replaced by suitable alternatives where these are economically and technically viable, whilst at the same time ensuring the good functioning of the EU internal market. A description of the procedure to include substances in the authorisation process is available in the Regulations section of ECHA's website at: <https://echa.europa.eu/substances-of-very-high-concern-identification-explained>.

SVHCs which may be included in Annex XIV to REACH, and for which thereby the authorisation requirement will be established, are substances with the following properties:

Legal reference	Hazard class	Identification criteria
Article 57 (a) REACH	Carcinogenicity category 1 A/B	Section 3.6 of Annex I to the Regulation (EC) No 1272/2008 (CLP Regulation)
Article 57 (b) REACH	Germ cell mutagenicity category 1 A/B	Section 3.5 of Annex I to the CLP Regulation
Article 57 (c) REACH	Reproductive toxicity category 1 A/B, adverse effects on sexual function and fertility or on development	Section 3.7 of Annex I to the CLP Regulation
Article 57 (d) REACH	Persistent, bioaccumulative and toxic (PBT)	Annex XIII to the REACH Regulation (as amended ³)
Article 57 (e) REACH	Very persistent and very bioaccumulative (vPvB)	Annex XIII to the REACH Regulation (as amended ³)

³ Commission Regulation (EU) No 253/2011 of 15 March 2011 amending Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and restriction of Chemicals (REACH) as regards Annex XIII (OJ L 69/7, 16.3.2011)

<p>Article 57 (f) REACH</p>	<p>Equivalent level of concern to those of other substances listed in point (a) to (e) of Article 57 of REACH⁴. It is clear from ECHA's decisions identifying SVHCs that, on a case-by-case basis, at least substances with the following hazard properties may give rise to an equivalent level of concern:</p> <ul style="list-style-type: none"> • Respiratory sensitising properties (Article 57(f) - human health) • Specific target organ toxicity after repeated exposure (Article 57(f) - human health) • Endocrine disrupting properties (Article 57(f) - human health) • Endocrine disrupting properties (Article 57(f) - environment) 	<p><i>Substances - such as those having endocrine disrupting properties or those having persistent, bioaccumulative and toxic properties or very persistent and very bioaccumulative properties, which do not fulfil the criteria of Article 57 points (d) or (e) - for which there is scientific evidence of probable serious effects to human health or the environment which give rise to an equivalent level of concern to those of other substances listed in Article 57 points (a) to (e) and which are identified on a case-by-case basis in accordance with the procedure set out in Article 59 of REACH.</i></p>
-----------------------------	---	---

3. Preparation of an Annex XV dossier for the identification of substances of very high concern (Article 57 of REACH)

3.1 Before starting to prepare a dossier

Before initiating work on an Annex XV SVHC dossier, the Authority should check whether another Member State or the Agency is already preparing such a dossier on the same substance or whether the substance is currently subject to any pre-regulatory (screening, dossier evaluation, substance evaluation, hazard assessment (PBT/vPvB/Endocrine Disruption), Risk Management Option Analysis (RMOA)) or regulatory (e.g. harmonised classification and labelling, SVHC, authorisation, restriction) processes under REACH or CLP. This can be done by checking the Activities Coordination Tool (ACT) available *via* the Portal Dashboard for MSCAs⁵.

If another process is under consideration or has been initiated for the same substance, it is recommended to contact the other Authorities working on the substance to ensure that work is not duplicated.

Where the SVHC identification is based on an adverse effect for which classification criteria have been defined in the CLP Regulation and the substance has not yet been classified for such adverse effect, it is strongly recommended to first use the process set out in the CLP Regulation to conclude whether these criteria are met before proposing such substance to be identified for inclusion in the candidate list. Where the identification is not based on effects for which there are classification criteria in the CLP Regulation, more information and advice on how to assess and structure the relevant information can be found within this guidance and in related documents on the support section of ECHA's website:

<https://echa.europa.eu/support/authorisation/substances-of-very-high-concern-identification>.

⁴ Hereinafter referred to as 'substances of equivalent level of concern'

⁵ <https://idp-authority.echa.europa.eu/idp/>

3.2 Preparing a dossier

As soon as the Authority starts work on preparing the Annex XV dossier, they should inform ECHA (using the webform that is available in MSCA Portal Dashboard), so that the ACT entry for the substance can be updated promptly and the information on the intention to prepare an Annex XV SVHC dossier can be included in the Registry of SVHC intentions list⁶ and PACT⁷ on ECHA's website.

An Annex XV SVHC dossier consists of an Annex XV SVHC report:

- The information provided in **Part I** of the report is used to make the hazard based assessment of the properties and to confirm whether the substance can be successfully identified as an SVHC.
- The information in **Part II** of the report is used in the next step of the authorisation process, *i.e.* the prioritisation of substances from the Candidate List to be recommended for inclusion in Annex XIV to REACH (and become subject to the authorisation requirements). The **registration dossiers** are the **main source of information** for this part of the SVHC report. In addition, information from downstream user reports and classification and labelling notifications should be used. Furthermore, any other available relevant information can be used.

The Authority should (i) collect the relevant information, (ii) assess the information, (iii) compare it to the relevant criteria, (iv) draw conclusions as to whether the criteria are met and (v) document the information, assessment and conclusions in the Annex XV SVHC report.

The [Guidance on Information Requirements and Chemical Safety Assessment \(IR&CSA\)](#) contains detailed guidance on the interpretation of studies in relation to the individual criteria. The present guidance therefore does not discuss technical issues in relation to such studies. If the basis for the identification is Article 57 of REACH (a), (b) or (c), (*i.e.* it is Carcinogenic/Mutagenic/Toxic for Reproduction category 1A/B (CMR)), then it is sufficient to provide in Part I of the Annex XV SVHC report a reference to the respective entry in Annex VI of the CLP Regulation. If the basis for the identification is Article 57 (d), (e) or (f), then the Annex XV SVHC dossier should provide full details on how these criteria have been met.

Authorities should use the **annotated Annex XV template** when preparing an Annex XV report, proposing the identification of a substance as an SVHC. It is available on the support section of ECHA's website at: <https://echa.europa.eu/support/authorisation/substances-of-very-high-concern-identification>.

A IUCLID file no longer needs to be submitted together with the Annex XV report.

3.3 Further guidance and support

More detailed information and advice can be found in the support section of the ECHA website under "substances of very high concern identification": <https://echa.europa.eu/support/authorisation/substances-of-very-high-concern-identification>, including the annotated Annex XV template for the preparation of the Annex XV report.

⁶ <https://echa.europa.eu/registry-of-svhc-intentions>

⁷ <https://echa.europa.eu/pact>

Procedural advice including ECHA's procedure for handling the identification of SVHCs is also provided in the aforementioned section, with the aim of ensuring that it is the latest available information on emerging and developing issues, with respect to SVHCs.

The support section also contains guidance documents on the [identification and naming of substances under REACH and CLP and on IR&CSA](#). *Part C* and *Chapter R.11* of the [Guidance on IR&CSA](#) are particularly relevant for PBT/vPvB assessment, as these parts/chapters describe the scientific methods associated with the assessment.

3.4 What to do when an Annex XV dossier is not appropriate

There may be cases where the Authority carries out work on an Annex XV dossier but concludes that there is no need for a dossier at this point in time. In such cases, it is important that the work that has already been undertaken is not lost, but is made available for potential future work. Thus, the Authority is encouraged to record the results of the work it has carried out *via* the ACT (using the webform that is available in MSCA Portal Dashboard). A simple description of the work undertaken and the reasons why it was decided not to proceed may be sufficient.

**EUROPEAN CHEMICALS AGENCY
ANNANKATU 18, P.O. BOX 400,
FI-00121 HELSINKI, FINLAND
ECHA.EUROPA.EU**